Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma
Phase 2
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2010-01-11
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Intergroupe Francophone du Myelome
- Target Recruit Count
- 75
- Registration Number
- NCT01045681
- Locations
- 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷CHRU Hôpital Sud, Amiens, France
🇫🇷CHRU, Hôpital du Bocage, Angers, France
Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)
Phase 3
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Velcade-DexamethasoneDrug: Velcade-Thalidomide-Dexamethasone
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2009-06-01
- Lead Sponsor
- Intergroupe Francophone du Myelome
- Target Recruit Count
- 205
- Registration Number
- NCT00910897
- Locations
- 🇫🇷
Ch Avignon, Avignon, France
🇫🇷CH La Roche Sur Yon, La Roche Sur Yon, France
🇫🇷Ch Lorient, Lorient, France
Pharmacogenomic Study in Myeloma Patients Treated With Melphalan-prednisone-thalidomide or Lenalidomide-dexamethasone
Not Applicable
Completed
- Conditions
- Myeloma
- Interventions
- Drug: melphalan-prednisone-thalidomideDrug: lenalidomide-dexamethasone
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Intergroupe Francophone du Myelome
- Target Recruit Count
- 143
- Registration Number
- NCT00907452
- Locations
- 🇫🇷
Ch Dunkerque, Dunkerque, France
🇫🇷CHD Vendée, La Roche Sur Yon, France
🇫🇷CHRU Lille, Lille, France
© Copyright 2025. All Rights Reserved by MedPath